Publication
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Authors not recorded
N Engl J Med2004PMID 15201427stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerThymus Carcinomacivic_curation1.00
- drugImatinibcivic_curation1.00
- geneKITcivic_curation1.00
- variantKIT V560DELcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 15201427
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KIT V560DEL2 | ||||||||
| Imatinib | Thymus CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 5 | accepted | EID486In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib. PMID 15201427 · Ströbel et al., 2004 · Open in CIViC | civic |
| Imatinib Mesylate | Thymus CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7359Thymic Carcinoma with Overexpression of Mutated KIT (V560DEL) and the Response to Imatinib PMID 15201427 · Ströbel et al., 2004 · Open in CIViC | civic |